While 20–30% of colorectal cancers (CRCs) may arise from precursors with serrated glands, only 8–10% of CRCs manifest serrated morphology at diagnosis. Markers for distinguishing CRCs arising from ‘serrated’ versus ‘conventional adenoma’ precursors are lacking. We studied 36 human serrated CRCs and found CDX2 loss or BRAF mutations in ~60% of cases and often together (p=0.04). CDX2Null/BRAFV600E expression in adult mouse intestinal epithelium led to serrated morphology tumors (including carcinomas) and BRAFV600E potently interacted with CDX2 silencing to alter gene expression. Like human serrated lesions, CDX2Null/BRAFV600E-mutant epithelium expressed gastric markers. Organoids from CDX2Null/BRAFV600E–mutant colon epithelium showed serrated features, and partially recapitulated the gene expression pattern in mouse colon tissues. We present a novel mouse tumor model based on signature defects seen in many human serrated CRCs – CDX2 loss and BRAFV600E. The mouse intestinal tumors show significant phenotypic similarities to human serrated CRCs and inform about serrated CRC pathogenesis.https://doi.org/10.7554/eLife.20331.001
Colorectal cancers (CRC) have accumulated defects in oncogenes and tumor suppressor genes (TSGs) (Fearon and Vogelstein, 1990). Many CRCs likely arise via clonal outgrowth and evolution of an epithelial cell or cells in an adenomatous precursor lesion via so-called adenoma-carcinoma progression (Fearon, 2011; Fearon and Vogelstein, 1990). But, upwards of 20–30% of CRCs may arise via an alternative pathway, often termed the 'serrated pathway', to reflect the saw-tooth or serrated morphology of the epithelial glands in the presumptive benign precursor lesions (Bettington et al., 2013; Jass, 2007a; Langner, 2015). Serrated benign lesions arising in the colon and rectum include hyperplastic polyps (HPPs), sessile serrated adenomas/polyps (SSAs/SSPs), and traditional serrated adenomas (TSAs) (Bettington et al., 2013; Langner, 2015). HPPs comprise the vast majority of serrated benign lesions detected and are most often found in the distal colon and rectum (Bettington et al., 2013; Langner, 2015). SSAs/SSPs account for 5–20% of serrated benign lesions and arise more often in the proximal colon (Bettington et al., 2013; Langner, 2015). TSAs account for only about 1% of serrated benign lesions and arise mostly in the distal colon and rectum (Bettington et al., 2013; Langner, 2015). Some SSAs/SSPs and TSAs, such as those showing dysplasia, have potential to progress to CRC (Bettington et al., 2013; Jass, 2007a; Langner, 2015). HPPs do not show dysplasia and have generally been assumed to have negligible malignant potential (Bettington et al., 2013; Langner, 2015). However, in rare patients who develop HPPs along with other serrated colon polyps or in other patients with multiple and large HPPs, the lifetime risk of CRC is elevated (Jass, 2007b). Hence, all three serrated benign lesion subtypes may have malignant potential, with SSAs and TSAs having higher potential than HPPs.
Recurrent somatic mutations in CRCs affect roughly two-dozen different genes (Cancer Genome Atlas Network, 2012). Mutations in the APC and TP53 TSGs are found in about 80% and 60% of CRCs, respectively (Cancer Genome Atlas Network, 2012; Fearon, 2011). KRAS and BRAF oncogenic mutations are seen in roughly 40% and 10% of CRCs, respectively, and are mutually exclusive in a given CRC (Cancer Genome Atlas Network, 2012; Fearon, 2011). KRAS mutations most often result in missense substitutions at glycine codons 12 or 13, and BRAF mutations most often result in missense substitutions of glutamic acid (E) for valine (V) at codon 600 (V600E) (Cancer Genome Atlas Network, 2012; Fearon, 2011). Somatic BRAF mutations and loss or reduction of expression of the CDX2 homeobox transcription factor individually and concurrently have been associated with poor prognosis in CRC patients (Bae et al., 2015; Clarke and Kopetz, 2015; Dalerba et al., 2016; Landau et al., 2014).
BRAF mutations are found in 70–80% of SSAs/SSPs, whereas KRAS mutations are rare in these tumors (Bettington et al., 2013). BRAF mutations are found in about 70% of proximal colon HPPs and/or microvesicular histology HPPs, whereas KRAS mutations are found in up to 50% of HPPs in the distal colon and rectum and in goblet cell-rich histology HPPs. TSAs mostly have KRAS mutations (Bettington et al., 2013). In part because BRAF mutations are common in SSAs/SSPs and HPPs and not in conventional adenomas, it has been argued that CRCs arising from serrated precursor lesions may harbor BRAF mutations more often than CRCs arising from the conventional adenoma pathway (Bettington et al., 2013; Langner, 2015). APC mutations are rare or absent in serrated benign lesions and are perhaps also less common in CRCs arising from a serrated precursor (Bettington et al., 2013; Langner, 2015). Other molecular features suggested to be associated with serrated pathway CRCs include CpG island methylation phenotype high-frequency (CIMP-H) with p16INK4A and/or MLH1 gene silencing, with MLH1 silencing linked to the microsatellite instability-high (MSI-H) phenotype (Bettington et al., 2013; Jass, 2007a; Langner, 2015). Serrated pathway-type CRCs have also been suggested to express gastric epithelium markers, such as mucin 2 (MUC2), MUC5AC, MUC6 and annexin A10 (ANXA10) (Kim et al., 2015; Tsai et al., 2015; Walsh et al., 2013).
Although up to 20–30% of CRCs have been estimated to arise from benign serrated precursors (Bettington et al., 2013; Jass, 2007a; Langner, 2015), only 8–10% of CRCs manifest definitive serrated morphologic features at diagnosis, characterized by epithelial gland serration, intracellular and extracellular mucin, and absence of necrosis (Bettington et al., 2013; García-Solano et al., 2010; Mäkinen, 2007). CRCs with serrated morphology (hereafter referred to as ‘serrated CRCs’) are presumed to arise mostly from serrated precursor lesions (Bettington et al., 2013). Definitive biomarkers are lacking to identify the CRCs that arose from serrated precursors but lack serrated morphology at diagnosis. Importantly, clinicopathologic studies have suggested that serrated CRCs may pursue a more aggressive course than their conventional counterparts (García-Solano et al., 2011) Hence, to further define how molecular lesions may underlie the pathogenesis of CRCs arising from serrated precursors, we pursued in-depth molecular characterization of 36 CRCs with definite serrated morphological features at diagnosis, studying BRAF, KRAS, TP53, p16INK4A, Wnt, and CDX2 pathway defects by DNA sequencing or protein expression and CIMP-H and MSI-H status by standard marker analyses. Because frequent concurrent loss of CDX2 expression and BRAF mutation suggested their cooperation in the pathogenesis of serrated CRCs, we modeled concurrent biallelic inactivation of Cdx2 (Cdx2-/-) and expression of mutant BRAFV600E in adult mouse colon epithelium via conditional somatic gene targeting approaches. Tumors arising in the mice and organoids derived from gene-targeted epithelium were studied and compared to human serrated CRCs in order to inform knowledge of the molecular pathogenesis of serrated CRCs and to identify potential biomarkers of this group of poor prognosis tumors. Our novel mouse model should have utility for new prevention, diagnosis, and treatment approaches for this important biological and clinical group of CRCs.
We selected 36 CRCs meeting defined histopathological criteria for the diagnosis of serrated adenocarcinoma (Jass and Smith, 1992; Mäkinen et al., 2001; Tuppurainen et al., 2005), with representative images of serrated morphology CRCs studied shown in Figure 1—figure supplement 1. We carried out analyses of selected molecular alterations in the 36 CRCs, focusing on the following: (i) DNA sequence-based determination of KRAS codons 12, 13, and 61 and BRAFT1799A(encoding BRAFV600E) missense mutations; (ii) DNA-based analyses of MSI-H and CIMP-H status; (iii) immunohistochemical (IHC) studies of β-catenin, p53, MLH1, p16INK4A, and CDX2 to inform about the expression and functional status of selected TSG pathways and proteins; and (iv) IHC studies of annexin A10 (ANXA10) and MUC5AC to inform about aberrant gastric epithelial marker expression. We found loss or marked reduction of CDX2 expression in 21 (58%) tumors (Figure 1). Representative staining patterns for CDX2 and other selected proteins and pathways under study are shown in Figure 1—figure supplement 2. Frequent alterations in the 36 CRCs included strong nuclear staining for p53 protein in neoplastic cells in 21 (58%) of cases, consistent with expression of a missense mutant p53 protein, and BRAFT1799A missense mutation encoding BRAFV600E protein in 20 (56%) cases (Figure 1). Other changes seen included strong nuclear β-catenin staining, reflecting potential Wnt pathway mutations, in 19 (53%) cases; p16INK4a expression loss in 18 (50%) cases; the CIMP-H phenotype in 12 (33%) cases, with 8 of these 12 cases having lost p16INK4A expression; the MSI-H phenotype in 5 (14%) cases; MLH1 expression loss in 4 (11%) cases, all of which were MSI-H cases; and KRAS codon 12 or 13 mutation in 7 (19%) cases, all of which lacked BRAFT1799A mutations (Figure 1).
Because CDX2 loss/reduction was seen in 21 of the 36 (58%) CRCs and BRAF mutations were seen in 20 (56%) of cases, we sought to determine how CDX2 loss/reduction and BRAF mutations might be associated with specific clinical, pathological, or molecular features. We did not observe any statistically significant correlations between CDX2 loss/reduction or BRAFT1799A mutation and patient age, tumor location, or selected tumor histological features, other than the absence of ‘dirty necrosis’ was associated with BRAF mutations (p=0.03) (Figure 1—source data 1). However, we did find that CDX2 loss/reduction and BRAF mutations were seen concurrently in 15 (42%) cases (p=0.04) (Table 1 and Figure 1). Besides BRAF mutations, other features more commonly seen in CDX2-negative tumors were CIMP-H status (p=0.04); membranous staining for β-catenin throughout the tumor, including the invasive front, likely reflecting wild type status for Wnt pathway genes (e.g, APC and CTNNB1, encoding β-catenin) (p=0.05); and retention of p16INK4A expression (p=0.04) (Table 1 and Figure 1). BRAF mutations in these cases were associated with membranous staining for β-catenin (p=0.003), CIMP-H status (p=0.004), and ANXA10 expression (p<0.0001) (Table 1 and Figure 1). Interestingly, all 7 KRAS-mutant CRCs were CDX2-positive and lacked ANXA10 or MUC5AC expression, except for MUC5AC expression in one KRAS-mutant case (Figure 1).
Because the human serrated morphology CRCs frequently showed marked reduction or loss of CDX2 expression and BRAFT1799A mutations, we sought to address consequences of conditionally inactivating Cdx2 or expressing the BRAFV600E oncoprotein kinase in mouse adult intestinal epithelium, as well as concurrent alterations of both Cdx2 and BRAFV600E. We previously described CDX2P-CreERT2 transgenic mice, expressing a tamoxifen (TAM)-regulated Cre protein (CreERT2) under control of human CDX2 regulatory sequences (Feng et al., 2013). The transgene allows for TAM-inducible targeting of loxP-containing alleles in adult mouse terminal ileum, cecum, colon, and rectal epithelium. The median survival of CDX2P-CreERT2 Cdx2fl/fl mice treated with TAM to activate Cre function and inactivate both Cdx2fl alleles (Blij et al., 2012) in colon epithelium was greater than 480 days (Figure 2A). We also used the CDX2P-CreERT2 transgene to activate a conditionally oncogenic Braf allele (BrafCA), which expresses normal BRAF until subjected to Cre-mediated recombination, resulting in expression of a mouse-human hybrid V600E oncogenic protein under the control of Braf endogenous regulatory elements (Dankort et al., 2007). Regardless of the species of origin, we refer to this mutationally activated form of BRAF as BRAFV600E and the BrafCA allele after Cre-mediated recombination as BrafV600E for the sake of clarity. The median survival of CDX2P-CreERT2 BrafCA mice was greater than 480 days after TAM treatment (Figure 2A). In marked contrast, the median survival of CDX2P-CreERT2 Cdx2fl/fl BrafCA mice was 103 days after TAM treatment to concurrently target the Cdx2fl/fl and BrafCA alleles (Figure 2A). The median survival of mice with simultaneous targeting of one Apcfl allele together with Cdx2fl and BrafCA alleles was 158 days, indicating that inactivation of one Apc allele did not enhance tumor aggressiveness compared to the phenotype seen in CDX2P-CreERT2 Cdx2fl/fl BrafCA mice (Figure 2A).
In CDX2P-CreERT2 BrafCA mice treated with TAM, we observed marked hyperplasia in more than 90% of crypts in the terminal ileum, cecum, and proximal colon (Figure 2—figure supplement 1B). The intestinal epithelium in CDX2P-CreERT2 Cdxfl/fl mice treated with TAM showed marked hyperplastic changes and irregular bifurcation of the crypts, but no dysplastic features (Figure 2—figure supplement 1C). When the TAM-treated CDX2P-CreERT2 Cdx2fl/fl BrafCA mice were moribund, all of the mice had at least one large protuberant tumor (>10 mm) or multiple polypoid lesions at the proximal colon-ileal-cecal junction and each mouse had 2–6 independent tumor lesions with size >2 mm (Figure 2B and Figure 2—source data 2). All the tumors arising in CDX2P-CreERT2 Cdx2fl/fl BrafCA mice showed both serrated and mucin-rich histological components (Figure 2C). The serrated components had a distinct serrated architecture with irregular bifurcation of the glands, and the cells in these glands have eosinophilic and abundant cytoplasm, and vesicular nuclei with prominent nucleoli (Figure 2C). These characteristics closely resemble features of human serrated morphology CRCs. In the mucin-rich components, the glands were tubular or cystic, and lined by bland cuboidal and columnar cells containing abundant mucin (Figure 2C). Using DNA samples isolated from the serrated or mucin-rich regions by laser-capture microdissection, we found the mucin-rich components had only inactivated both Cdx2fl alleles, whereas the serrated histology epithelium had both Cdx2fl alleles and the BrafCA allele targeted (Figure 2—figure supplement 1D). In the seven TAM-treated CDX2P-CreERT2 Cdx2fl/fl BrafCA mice studied, from 17–50% of the tumor lesions showed evidence that the serrated glands had invaded into the submucosa, indicative of carcinoma (Figure 2D and Figure 2—source data 2). Stochastic inactivation of the remaining wild type Apc allele in the setting of Apc hemizygous state in intestinal epithelium could potentially be seen as progression event in tumors initiated by other genetic drivers, such as in the setting of Cdx2 biallelic inactivation and BRAFV600E activation. We found that combined TAM-mediated targeting of an Apcflallele together with the Cdx2fl and BrafCA alleles in CDX2P-CreERT2 Cdx2fl/fl BrafCA Apcfl/+ mice did not alter the histology of the tumor lesions compared to those arising in CDX2P-CreERT2 Cdx2fl/fl BrafCAmice with intact Apc alleles (Figure 2—figure supplement 1E). Furthermore, we saw no apparent selection for loss of the remaining wild type Apc allele in tumors arising in CDX2P-CreERT2 Cdx2fl/fl BrafCAApcfl/+ mice, as no β-catenin nuclear or cytoplasmic staining was seen in the CDX2P-CreERT2 Cdx2fl/fl BrafCA Apcfl/+ mouse tumor tissues studied (Figure 2—figure supplement 1E). Our findings indicate concurrent Cdx2 silencing combined with BRAFV600E expression in mouse intestinal epithelium leads to premature death of the mice, due to the development of intestinal tumors, including carcinomas, and the tumors recapitulate histological features of human serrated morphology CRCs.
Akin to the situation in human serrated morphology CRCs with CDX2 loss and BRAFT1799A mutations (Figure 1), ANXA10 expression was seen in the serrated components of the tumors arising in the TAM-treated CDX2P-CreERT2 Cdx2fl/fl BrafCA mice (Figure 3A). ANXA10 expression was not seen in any of the mucin-rich tumor components, where only Cdx2 inactivation was present and BRAFV600E expression was absent (Figure 3A). The BRAF protein functions as an upstream activator of mitogen-activated protein kinase (MAPK) signaling, and similar to ANXA10 expression, phospho-ERK expression, indicating MAPK activation, was detected only in the serrated components of tumors (Figure 3A). Similar to the infrequent nuclear or cytoplasmic β-catenin staining and strong MUC5AC expression seen in most CDX2-defective and BRAFV600E-mutant human serrated CRCs (Figure 1), we found membranous β-catenin staining, strong MUC5AC expression, and bromo-deoxyuridine (BrdU) incorporation (indicating DNA synthesis) in the serrated components of the tumors in the CDX2P-CreERT2 Cdx2fl/fl BrafCA mice (Figure 3B). No evidence for p53 nuclear protein accumulation was seen in the serrated and/or invasive components (Figure 3B). Consistent with a previous study showing that EGFR activation was found in majority of CRC cell lines harboring BRAFV600E mutation (Prahallad et al., 2012), the tumors arising in the TAM-treated CDX2P-CreERT2 Cdx2fl/fl BrafCAmice showed significant higher levels of phospho-EGFR expression, compared to very low level of phospho-EGFR in Cdx2−/−-mutant, BrafV600E-mutant, or normal control mouse cecal epithelium (Figure 4). All tumors from 5 CDX2P-CreERT2 Cdx2fl/fl BrafCAmice were MSS, and we did not detect significant methylation at the p16Ink4a promoter in the tumors (Figure 3—figure supplement 1). Overall, the findings suggest concurrent CDX2 and BRAFV600E defects are key instigating lesions in development of the serrated mouse tumors.
The canonical or β-catenin-dependent Wnt signaling pathway has a key role in regulating tissue stem cells near the small intestine and colon crypt base, in large part via regulation of various β-catenin/T cell factor (TCF) transcription pathway genes (Koo and Clevers, 2014). In most human adenomas and CRCs, Wnt pathway defects, most commonly APC inactivating mutations, lead to dysregulated β-catenin/T cell factor (TCF) transcription with resultant activation of genes normally restricted to intestinal stem cells in many neoplastic cells in the lesions (Fearon, 2011; Koo and Clevers, 2014). We studied Cdx2-mutant, BrafV600E-mutant, and Cdx2 BrafV600E double-mutant, as well as Apc-mutant mouse colon epithelium, for expression of transcripts for various intestinal stem cell markers and Wnt pathway genes, such as: Olfm4, Lgr5, Msi1, Cd133, Lrig1, Nkd1, Hopx, Bmi1, Cd44, Axin2, Mmp7, Ephb2, cMyc and Sox9. Compared to control colon tissues, only Olfm4, Mmp7 and Sox9 expression were markedly increased in tumor tissues from the CDX2P-CreERT2 Cdx2fl/fl BrafCA mice (Figure 3—figure supplement 2A and B). Expression of Olfm4, Mmp7 and Sox9 transcripts was also markedly upregulated in proximal colon tissues from the CDX2P-CreERT2 Cdx2fl/fl mice. Expression of all of these presumptive stem cell and Wnt pathway genes, was markedly increased in Apc-mutant mouse colon tissues (Figure 3—figure supplement 2A and B). Consistent with our immunohistochemical studies, Muc5ac, Anxa10 and Pdx1 gene expression was increased in the Cdx2−/− BrafV600E serrated mouse tumors (Figure 3—figure supplement 2C).
To address the basis for the major collaborative effects of Cdx2 inactivation and BrafV600E activation in tumorigenesis, we undertook global gene expression analyses of normal colon epithelium, Cdx2−/−-mutant, BrafV600E-mutant, Cdx2−/−BrafV600E-mutant, and Apc-mutant colon epithelium. The principal components analysis showed the Cdx2−/− BrafV600E mutant epithelium clearly had distinct global patterns of gene expression from that of normal colon epithelium or mutant colon epithelium of the single mutant genotypes (Figure 5A). The gene expression patterns in Cdx2−/−BrafV600E-mutant epithelium indicated that combined Cdx2 inactivation and BrafV600E activation had very strong cooperative interactions in altering the expression of a large number of genes, with many genes dramatically activated in expression and a smaller collection of genes dramatically down-regulated (Figure 5B). Interestingly, notwithstanding the data above showing that the ANXA10 protein was strongly expressed in human serrated morphology CRC and mouse Cdx2−/− BrafV600E serrated tumor epithelium, it was still a surprise that Anxa10 was the top activated gene in the Cdx2−/− BrafV600E-mutant epithelium (Figure 5B). Cdx2 loss or BrafV600E expression alone had only modest effect on Anxa10 expression relative to levels in control epithelium, whereas concurrent Cdx2 and BrafV600E defects led to a roughly 100-fold activation of Anxa10 (Figure 5B). Interestingly, the Pla2g2a gene, which encodes a secretory phospholipase A2 protein and which is also known as Mom-1 (modifier of multiple intestinal neoplasia 1) for its defined role as a potent genetic modifier of the ApcMin intestinal neoplasia phenotype (Cormier et al., 1997), was a non-induced gene in Cdx2−/− BrafV600E -mutant epithelium compared to its induction in Cdx2−/− mutant, BrafV600E-mutant, or Apc-mutant epithelium (Figure 5B). The top pathways for activated gene expression patterns in the Cdx2−/− BrafV600E-mutant epithelium were epithelial-mesenchymal transition, KRAS signaling, and hypoxia, and the top pathways for down-regulated gene expression were cholesterol homeostasis, adipogenesis, and xenobiotic metabolism (Table 2).
To address the cooperative effects of CDX2 and BRAF function in regulating gene expression in human CRCs, we first compared our mouse gene signature to 212 human CRC samples available in TCGA project data (https://gdac.broadinstitute.org/) and that also have mutation data. Among these samples, we compared the 18 samples that had low CDX2 and BRAF V600E mutations to the 104 samples with high CDX2 that were not BRAF mutant, and selected the genes with p-values of <0.01 (two-sample T-test) and fold-changes of >1.3 between the two groups. Then, we computed the intersection of this selection to the similar selection we had performed in our mouse data to ask for significant Cdx2 by Braf interactions. We observed strong association between our mouse data and human CRC data with significant enrichment of genes found ‘up’ in both data-sets as well as ‘down’ in both data-sets, and few disagreements between both data-sets (p=4.5×10−49, Mantel-Haenszel Chi-Square test of association) (Figure 5 and Figure 5—source data 2). In addition, we also compared our mouse gene signature to expression data for 8 serrated and 29 conventional CRCs obtained from GEO series GSE4045 (called here Finnish data) (Laiho et al., 2007). Again, the genes that showed strong cooperative interaction between Cdx2 loss and BrafV600E expression in the mouse colon tumors (either up or down) were found to be significantly enriched in human serrated CRCs vs. conventional CRCs (p=1.4×10−11) (Figure 5—source data 2). Our findings suggested that the gene signature found in our Cdx2-/-/BrafV600E mouse model is highly instructive to identify the serrated subset of human CRCs.
The regulation of PDX1 homeobox transcription factor expression by CDX2 and BRAF in mouse colon tissues was of interest to us, given the role of homeobox proteins in cell-fate specification. Thus, we pursued in-depth immunohistochemical studies of PDX1 expression in selected mouse and human tissue specimens. In the normal mouse gastro-intestinal tissues studied, only gastric antrum epithelium and duodenum epithelium showed positive staining for PDX1, with no staining in epithelium from terminal ileum, cecum, colon and rectum (Figure 6—figure supplement 1). In contrast, strong PDX1 staining was seen in colon epithelium from CDX2P-CreERT2 Cdx2fl/fl BrafCA mice (Figure 6A). Strong and diffuse PDX1 staining was also seen in colon epithelium of CDX2P-CreERT2 Cdx2fl/fl mice (Figure 6—figure supplement 1). Activation of PDX1 expression was seen in colon epithelium of CDX2P-CreERT2 Cdx2fl/fl mice as early as 7 days after TAM injection to target the Cdx2 alleles (Figure 6—figure supplement 1). While strong PDX1 expression was seen in the majority of neoplastic cells in the tumors arising in the CDX2P-CreERT2 Cdx2fl/fl BrafCA mice (Figure 6A), PDX1 expression was largely restricted to apical region epithelial cells in colon epithelium of CDX2P-CreERT2 Cdx2fl/fl mice (Figure 6—figure supplement 1).
We then assessed the 36 serrated morphology human CRC cases, finding that 30 (83.3%) had strong PDX1 expression, including all 26 of the cases with CDX2 loss/reduction and/or BRAFT1799A mutations (Figure 1 and Figure 6B). To assess whether reduction or loss of CDX2 expression and ectopic PDX1 expression were also features of benign serrated colorectal lesions, we studied CDX2 and PDX1 expression in four goblet cell-rich histology HPPs, ten microvesicular histology HPPs, six SSAs/SSPs, and four TSAs. While CDX2 expression was retained in all goblet cell-rich histology HPPs, all 20 of the other benign serrated lesions studied had greatly reduced or absent CDX2 expression (Figure 6C). Moreover, induction of PDX1 expression was seen in all benign serrated lesion types (Figure 6C) and in all 24 benign lesions studied.
Because of the robust expression of PDX1 in all 24 of the serrated benign lesions studied and in 83.3% of the serrated morphology CRCs studied, we sought to assess the expression of PDX1 as well as CDX2 and ANXA10 expression in a large collection of CRCs not selected for any specific morphologic features. We found PDX1 was expressed in 132 (33%) of the 395 CRCs studied (Figure 6—source data 1), a percentage which is curiously not far from the upper estimate that 30% of CRCs may arise through a serrated pathway. Strong staining for CDX2 was seen in 287 (73%) of the 395 CRCs, with reduced but detectable CDX2 staining in 73 (18%) of the 395 cases and loss of CDX2 expression in 35 (9%) of the 395 cases (Figure 6—source data 1). ANXA10 expression, which was seen in 24 (67%) of the 36 human serrated CRCs, was only expressed in 26 (7%) of the 395 CRCs. These findings on ANXA10 expression, based on our data showing that only about 2/3 of serrated morphology CRCs express ANXA10, are not inconsistent with the published literature indicating that about 8–10% of all CRCs have serrated morphology. Because the 395 CRCs were represented as very limited tumor regions in the tissue microarray format, we could not reliably assess relationships of PDX1, CDX2 and ANXA10 staining in these CRCs relative to serrated morphology features.
To further assess how concurrent Cdx2 inactivation and BRAFV600E expression alters colon epithelial cell phenotypes, we studied organoids derived from normal and mutant mouse colon epithelium. Normal mouse colon epithelium-derived organoids formed uniform glandular structures in the presence of media supplemented with Wnt3a, R-spondin, noggin, epidermal growth factor (EGF), and hepatocyte growth factor (HGF) (Figure 7). The cells in the normal epithelium-derived organoids lacked dysplasia and resembled normal columnar colon epithelial cells. Apc-mutant (Apc−/−) mouse colon epithelium formed organoids in the absence of Wnt3a and R-spondin supplementation, as expected for cells with bi-allelic Apc mutations and constitutive activation of β-catenin/TCF transcription. The Apc−/− epithelium-derived organoids were larger than normal epithelium-derived organoids, and the cells showed dysplasia, with larger and more irregularly shaped nuclei containing open chromatin and a loss of the normal basal polarity of the nuclei (Figure 7). Organoids derived from Cdx2Null mouse colon epithelium were grown in the presence of the full growth factor supplementation, and the organoids showed minimal if any alterations in morphology relative to organoids derived from normal colon epithelium (Figure 7). Organoids derived from CDX2Null/BRAFV600E-mutant epithelium could be grown without EGF supplementation of the media, due presumably to constitutive BRAF→MEK1/2→ERK1/2 MAP kinase signaling driven by the BRAFV600E oncoprotein kinase. Initially, roughly 25% of the organoids derived from the CDX2Null/BRAFV600E-mutant epithelium showed serrated glandular structures, with invaginations of epithelial cells into the organoid lumen, and epithelial cells with eosinophilic or clear and abundant cytoplasm, vesicular nuclei with distinct nucleoli, and loss of basal polarity of the cells, closely resembling mouse and human epithelium with serrated morphology (Figure 7). CDX2 expression was seen in all organoids where Cdx2 gene function remained intact (Figure 7). Strong and homogeneous PDX1 expression was found only in the CDX2Null/BRAFV600E-mutant epithelium. After three-four in vitro passages of the CDX2Null/BRAFV600E-mutant organoids, we observed a significant decrease in the percentage of organoids displaying serrated morphology, suggesting that serrated morphologic appearance as a phenotypic trait may not be stable in some neoplastic cell populations over time. To further explore the usefulness of the CDX2Null/BRAFV600E-mutant organoids as a model system, we studied the gene expression by q-RT PCR for the top 15 genes showing positive interaction of CDX2 silencing and BRAFV600E expression in mouse colon tissues and five more ‘up’ genes that are shared by our mouse data-set and one of the two human CRC data sets – the TCGA data-set or the Finish data-set (Figure 5—source data 3, marked as red). Interestingly, only 4 out of the 20 genes up-regulated in the in vivo setting (i.e., Npy, Gkn2, Ivl and Tmprss11e) showed significant cooperative interaction between CDX2 silencing and BRAFV600E expression in the organoid model system (Figure 8A and C). Lower expression of Anxa10 was found in the CDX2Null/BRAFV600E-mutant organoids compared to the normal control or BrafVE organoids (Figure 8A and C). The expression of Npy, Gkn2, Ivl and Tmprss11e as well as Anxa10 in CDX2Null/BRAFV600E-mutant organoids was markedly inhibited by MEK1/2-inhibitor (AZD6244) treatment. The effectiveness of AZD6244 treatment was verified by its inhibitory effect on expression of MAPK target genes, Dusp6 and Fos, in all the organoids treated (Figure 8B and C) and was also confirmed by its ability to significantly reduce the level of phospho-ERK (Figure 8—figure supplement 1).
Studies of the molecular pathogenesis of CRC have often focused on a conventional adenoma-carcinoma progression model (Fearon, 2011; Fearon and Vogelstein, 1990). But, clinical, pathological, and molecular data suggest perhaps upwards of 20–30% of CRCs may arise from benign lesions with serrated glands, rather than conventional adenomas (Bettington et al., 2013; Jass, 2007a; Langner, 2015). One challenge in studying the pathogenesis of the CRCs that arise from serrated precursors is there are no known biomarkers that can definitively distinguish CRCs that arose from serrated lesions from CRCs arising from conventional adenomas (Bettington et al., 2013; Jass, 2007a; Langner, 2015). Another issue is that while an estimated 20–30% of CRCs may arise from a serrated precursor lesion, at diagnosis, only about 8–10% of CRCs manifest serrated morphological features (Bettington et al., 2013). In the work presented here, we have provided new insights into the molecular pathogenesis of serrated morphology CRCs. We have described a novel mouse tumor model based on two signature molecular lesions present in many human serrated morphology CRCs, and we provide evidence that the mouse tumors manifest significant phenotypic similarities to human serrated morphology CRCs. We have also highlighted new expression markers that may be useful for studying further the serrated precursor-CRC relationship.
We found marked loss or reduction of the CDX2 homeobox transcription factor and BRAF somatic mutations were both prevalent in serrated morphology CRCs, with concurrent CDX2 loss and BRAFT1799A mutation in 15 of the 36 (42%) cases. To address the potential cooperating roles of CDX2 loss and BRAFV600E expression in human serrated morphology CRCs, we studied the consequences of conditional inactivation of Cdx2 alleles, expression of a BRAFV600E mutant protein, or concurrent Cdx2 inactivation and BRAFV600E mutant protein expression in mouse distal intestinal epithelium. We found concurrent Cdx2 inactivation and BRAFV600E expression had dramatic effects on mouse survival relative to either defect alone, with a median survival for the CDX2-CreERT2 Cdx2fl/fl BrafCA mice of only 103 days after conditional gene targeting. The mice developed large tumors in the terminal ileum, cecum and/or proximal colon, and the tumors displayed serrated histological features. A subset of the tumors arising in each CDX2-CreERT2 Cdx2fl/fl BrafCA mouse had clear evidence of invasion (carcinoma). Molecular analyses of the mouse tumors revealed that concurrent Cdx2 loss and BRAFV600E expression had major cooperating effects in altering gene expression. Cooperating effects of CDX2 and BRAF function in modulating expression of selected genes could also be seen in CDX2Null/BRAFV600E-mutant organoids. However, the organoid system did not model the cooperative effects of CDX2 and BRAF defects for the vast majority of the genes found to be upregulated in CDX2Null/BRAFV600E-mutant epithelium in vivo, raising some questions about the utility of in vitro organoid model for recapitulating cooperation between CDX2 and BRAF. Human serrated morphology CRCs and mouse Cdx2−/− BrafV600E-mutant tumor epithelium aberrantly expressed a number of gastric epithelial markers, including ANXA10, MUC5AC, and PDX1.
Prior studies have emphasized the view that SSAs/SSPs, especially SSAs/SSPs arising in the proximal colon, are the serrated tumors with the greatest risk of progression to CRC (Bettington et al., 2013; Jass, 2007a; Langner, 2015). Besides the BRAFT1799A mutations that are often present in SSAs/SSPs, it has been argued that CRCs arising from proximal colon SSAs/SSPs will often manifest the CIMP-H and MSI-H phenotypes, with the CIMP-H phenotype reflecting hypermethylation of selected promoters, including that for the MLH1 gene, leading to the MSI-H phenotype(Bettington et al., 2013; Jass, 2007a; Langner, 2015). Some prior studies have shown CRCs with somatic BRAFT1799A mutations, and that were not selected by morphological appearance, more often arise in the proximal colon than the distal colon or rectum, and these particular CRCs more often manifest the CIMP-H and MSI-H phenotypes than the bulk of CRCs(Bettington et al., 2013; Jass, 2007a). However, in contrast to the notion that CRCs arising from serrated precursors are nearly always or even predominantly right-sided lesions with CIMP-H and MSI-H phenotypes, 17 of the 36 serrated morphology CRCs that we studied were rectal lesions and four were distal colon lesions, with only 15 of the 36 serrated morphology CRCs arising in the proximal colon. We did observe the CIMP-H phenotype more frequently in the human serrated morphology CRCs with CDX2 loss and BRAFT1799A mutations (i.e., CIMP-H in 10 of 15 such cases) than in the CRCs lacking concurrent CDX2 loss and BRAFT1799Amutations (i.e., CIMP-H in only 3 of 21 such cases). However, our 10 CIMP-H cases with concurrent CDX2 loss and BRAFT1799A mutation included four cases arising in the rectum and only 2 of 10 CIMP-H cases displayed the MSI-H phenotype and had lost MLH-1 protein expression. Hence, our data imply that a potentially significant fraction of serrated morphology CRCs may arise from precursor lesions other than proximal colon SSAs/SSPs. Also, while CDX2-null/low and BRAFV600E-mutant serrated morphology CRCs often manifested the CIMP-H phenotype, most serrated morphology CRCs lacking concurrent CDX2 and BRAFV600E defects did not manifest the CIMP-H phenotype. In addition, the MSI-H phenotype was not significantly enriched in our 36 serrated morphology CRCs as a group (5 of 36 cases – 14%) relative to the established prevalence of 15% in CRCs in general (Bettington et al., 2013; Cancer Genome Atlas Network, 2012; Fearon, 2011). Consistent with our findings, a prior study reported that the MSI-H phenotype was only seen in 16% of serrated morphology CRCs (García-Solano et al., 2010).
The mouse model of serrated intestinal tumorigenesis, including carcinomas, that we describe here, based on concurrent Cdx2 inactivation and BRAFV600E expression in distal mouse intestinal epithelium, is the first serrated mouse colon cancer model to our knowledge to be based on two signature defects common to a significant subset of human serrated morphology CRCs. Prior serrated tumorigenesis models using conditional activation of a mutant Kras allele in the mouse intestinal tract together with concurrent p16Ink4a/Arf or Pten TSG inactivation(Bennecke et al., 2010; Davies et al., 2014), can promote outgrowth of dysplastic lesions and occasionally progression of some lesions to carcinoma. However, our data suggest potentially uncertain relevance of Kras-mutation-based mouse models with respect to serrated morphology human CRCs, as only seven of the 36 (20%) serrated morphology CRCs that we studied had KRAS mutations and only two of the seven KRAS-mutant serrated CRCs had lost p16INK4A expression. Besides the modest-moderate frequency of KRAS mutations in human serrated CRCs, the low overall frequency of PTEN mutations in human primary CRCs raises some questions about the relevance of mouse models combining Kras activation and Pten inactivation to model serrated CRC. A prior mouse model has been reported where BrafV600E conditional activation in small intestine in concert with p16Ink4a inactivation led to tumors with some serrated morphological features(Carragher et al., 2010). While p16INK4A expression loss is common in BRAFV600E-mutant human serrated CRCs, the prior BRAFV600E-expressing and p16Ink4amutant mouse model developed tumors in many tissues besides the intestinal tract (e.g., liver, lung, stomach), limiting its utility. In another model of serrated pathway tumorigenesis, Rad et al showed that activation of BrafV600E specifically in mouse intestinal tissues instigated hyperplasia and dysplasia with serrated features, and a very small subset of the tumors progressed over time to invasive carcinomas (Rad et al., 2013). However, the BRAFV600E-induced dysplastic lesions in this model showed features akin to human traditional serrated adenomas (TSA), which the authors reasoned might be due in part to the predominant location of the tumors arising in mouse small intestine. Our human serrated CRC data highlight additional gene defects that may cooperate with Cdx2 inactivation and BRAFV600E expression in our mouse model, such as p16Ink4a and/or Trp53 mutations, and restricted gene targeting to the terminal ileum, cecum and colon as permitted with the CDX2-CreERT2 transgene may be useful in future studies to determine how additional gene alterations collaborate with the CDX2 and BRAFV600E defects in tumor progression and metastasis.
Among a number of poorly understood issues in the serrated precursor-CRC field is how to reconcile the estimate that upwards of 20–30% of CRCs may arise from serrated precursor lesions, yet only 8–10% of CRCs manifest serrated morphology at diagnosis. One possible explanation is that during progression to CRC the serrated morphological features present in a precursor cell population may be lost, due in part to the initiating gene lesions and additional genetic and epigenetic alterations, changes in the tumor microenvironment, or other mechanisms. Consistent with the view that phenotypic drift during neoplastic progression might contribute to why many fewer CRCs manifest serrated morphology at diagnosis relative to the fraction of CRCs estimated to arise from serrated precursors, we found the propensity of the CDX2Null/BRAFV600E-mutant mouse organoids to manifest serrated morphological features in culture decreased substantially over relatively few passages. Another possible issue of interest for the field is which biomarkers might identify the CRCs arising from serrated precursor lesions. Our data on ANXA10 and PDX1 expression may be interesting in this regard. Our findings indicate ANXA10 may not be expressed in all serrated morphology CRCs, with ANXA10 most often expressed in those cases with CDX2 loss and/or BRAFT1799A mutations. On the other hand, PDX1 expression was seen in all benign serrated lesions studied and 83.3% of the 36 serrated morphology CRCs as well as 33% of nearly 400 CRCs selected without regard to specific morphological features. Further studies to define how PDX1 expression and perhaps ANXA10 expression might be used together with other biomarkers to identify the CRCs that arose from serrated precursor lesions may have possible diagnostic and prognostic relevance. Yet another unresolved issue for the serrated precursor-CRC field, and potentially one of greater significance for colorectal cancer screening recommendations in the general population in the future, is whether a potentially significant fraction of human CRCs arise from benign serrated lesions that are currently presumed to be of low malignant potential, such as HPPs in the distal colon and rectum, with or without BRAFT1799Amutations, or proximal colon serrated lesions with KRAS mutations. The basis for this proposal is that our studies indicate that many human serrated morphology CRCs may arise in the distal colon and rectum, about half of the rectal and distal colon lesions lack BRAFT1799A mutations, and five of the seven KRAS-mutant serrated CRCs we studied arose in the proximal colon. Further in-depth studies of benign and malignant serrated morphology colorectal lesions in man and longitudinal studies of tumor features and progression in our mouse model may help to inform some of these and other issues about the pathogenesis and clinical features and significance of serrated benign lesions and serrated CRCs.
The diagnosis of serrated morphology CRC was based on established histopathological criteria (Mäkinen, 2007; Tuppurainen et al., 2005; Bateman, 2014). Serrated morphology CRC was characterized by evident epithelial serrations composed only of epithelium or epithelium and basement membrane material, clear or eosinophilic and often abundant cytoplasm, vesicular nuclei, absence of or less than 10% necrosis of the total surface area, mucin production, and the presence of serrations and eosinophilic cell globules and rod-like structures floating freely in the mucus. The diagnostic sub-classification of the 36 serrated CRCs studied here was based on previously proposed criteria from Snover and Torlakovic et al (Snover, 2011; Torlakovic et al., 2003). Serrated CRCs of each of the three known histological sub-groups, arising in Japanese patients, were included, with the vast majority of cases representing the serrated subtype (n = 30) and only a minority reflecting the mucinous (n = 4) or trabecular (n = 2) subtypes of serrated CRC. The 36 serrated morphology CRCs were studied in accordance with the Ethical Guidelines for Human Genome/Gene Research enacted by the Japanese Government. Hematoxylin- and eosin-stained tissue sections of the human serrated morphology CRCs were evaluated by three board-certified surgical pathologists with expertise in gastrointestinal cancer diagnosis (N.S., K.S., W.Y.). We also studied tissue sections of four Goblet cell rich HPP, 10 Microvesicular HPP, 6 SSA/P, and 4 TSA cases obtained from the University of Michigan tissue procurement service through an Institutional Review Board-approved protocol.
DNA was extracted from formalin-fixed, paraffin-embedded serrated CRC specimens. Areas in which tumor cells were most dense were delineated by light microscopic analysis of tissue slides. The corresponding areas were marked on 10 serial, unstained tissue slides; the marked areas were then manually scraped from the glass slides. DNA was extracted using QIAamp DNA FFPE Tissue Kit (QIAGEN, Valencia, CA). BRAF codon 600 flanking sequences were amplified by PCR. PCR amplifications were performed with GoTaq Green Master Mix (Promega, Madison, WI) following the standard 3-temperature PCR protocol, with denaturing at 94°C, annealing at 55°C, and extension at 72°C. The PCR products were extracted using QIAquick Gel Extraction Kit (QIAGEN) and submitted for direct Sanger sequencing. The obtained sequences were analyzed and aligned with BRAF reference sequence, NM_004333.4. Cases apparently negative for BRAFT1799A were evaluated for alternative mutations in KRAS codons 12, 13, and 61 by PCR amplification and direct Sanger sequencing of PCR amplification products. Primer sequences were: KRAS codon 12/13, 5’- gcctgctgaaaatgactgaat −3’ and 5’- ggtcctgcaccagtaatatgc −3’; KRAS codon 61, 5’- ccagactgtgtttctcccttc −3’ and 5’-aaagaaagccctccccagt-3’; BRAF codon 600, 5’- ccacaaaatggatccagaca −3’ and 5’- cctaaactcttcataatgcttgctc −3’.
BrafCA (aka Braftm1Mmcm) mice carry a conditional allele of Braf that encodes normal BRAF prior to Cre-mediated recombination, after which it encodes a mouse-human hybrid V600E oncogenic protein, were previously described (Dankort et al., 2007). Regardless of species of origin, we refer to this mutationally activated form of BRAF as BRAFV600E and the BrafCA allele after Cre-mediated recombination as BrafV600E for the sake of clarity. CDX2P-CreERT2 transgenic mice (Feng et al., 2013) were intercrossed with mice homozygous for a Cdx2 targeted allele (Cdx2fl/fl) (Blij et al., 2012) and/or the BrafCA mice. Cre-mediated conversion of the BrafCA allele to encode BRAFV600E and the deletion of Cdx2 were assessed by PCR as previously described (Blij et al., 2012; Dankort et al., 2007; Feng et al., 2013). Apcfl mice have been previously described (Shibata et al., 1997). Littermates differing in specific genotypes were used for the survival work and all tissue and molecular work. Animal husbandry and experimental procedures were carried out under approval from the University of Michigan’s Institutional Animal Care and Use Committee (PRO00005075) and according to Michigan state and US federal regulations. All the mice were housed in specific-pathogen free (SPF) conditions. After weaning, rodent 5001 chow and automatically supplied water were provided ad libitum to mice.
Adult mice (2–3 months of age) carrying the CDX2P-CreERT2 transgene were injected intraperitoneally with TAM (Sigma-Aldrich, St. Louis, MO) dissolved in corn oil (Sigma-Aldrich). For two daily TAM doses, we used 150 mg/kg weight per dose. Animals were euthanized and analyzed at various time points after the final injection given.
Organoids were derived from proximal colon of the following mice: (1) wild-type mice (6-week age); (2) CDX2P-CreERT2 Apcfl/fi mice (24 days after TAM injection); (3) CDX2P-CreERT2 Cdx2fl/fl mice (three weeks after TAM injection); (4) CDX2P-CreERT2 BrafCA mice (3 months after TAM injection); (5) CDX2P-CreERT2 Cdx2fl/fl BrafCA mice (4 months after TAM injection). Mice were first treated with TAM to induce gene targeting and/or tumor formation, and then colonic organoids were generated and propagated using previously described ‘TMDU protocol’ (Yui et al., 2012) with minor modifications. The proximal colon and tumor lesions in the proximal colon were removed, minced into small pieces, and suspended in 12.5 ml of DMEM (Life Technologies Corporation, Grand Island, NY) supplemented with 100 U/ml penicillin (Life Technologies Corporation), 100 μg/ml streptomycin (Life Technologies Corporation), 50 μg/ml gentamicin (Life Technologies Corporation) and 1% FBS (complete DMEM), to which 15 mM EDTA were added. The mixture was shaken for 1 hr at 4°C. The released crypts were washed extensively, pelleted, and resuspended in 200 μl of the Matrigel (Corning, Bedford, MA) and placed in 3 wells of 24-well plates. After polymerization, 500 μl of ‘TMDU’ medium, which has advanced DMEM/F12 (Life Technologies Corporation) containing 2 mM L-Glutamine (Life Technologies Corporation), 10% Wnt3A (Barker et al., 2010), 10% R-spondin2 (Bell et al., 2008) conditioned-media and 100 ng/ml Noggin (Peprotech, Rocky Hill, NJ), 20 ng/ml mouse EGF (Life Technologies Corporation), 50 ng/ml mouse HGF (R and D Systems, Minneapolis, MN), and 10 μM Y-27632 (R and D Systems), was added to each well for organoids from wild-type mice and CDX2P-CreERT2 Cdx2fl/fl mice. We used TMDU medium minus mEGF for the organoids from CDX2P-CreERT2 BrafV600Eand CDX2P-CreERT2 Cdx2fl/fl BrafV600E mice, and used TMDU medium with Wnt3a and R-spondin2 conditional media replaced by advanced DMEM/F12 for organoids from CDX2P-CreERT2 Apcfl/fl mice. The medium was changed every 2–3 days. The organoids were split at 1:3 ratios every 7–8 days. For gene expression study, organoids were generated from epithelium at proximal colon-cecum junction of wild-type (Control), CDX2P-CreERT2 Cdx2fl/fl (Cdx2KO), CDX2P-CreERT2 BrafCA (BrafVE), and CDX2P-CreERT2 Cdx2fl/fl BrafCA (Cdx2KOBrafVE) mice after 7 days following two daily doses of TAM (150 mg/kg) injection. The organoids were plated in Matrigel for 3 days, and then were treated with DMSO or 6 μM of MEK1/2 inhibitor, AZD6244 (Cayman Chemical Company, Ann Arbor, MI), daily for two consecutive days before harvest for RNA extraction.
Mouse tissues were prepared for paraffin embedding, as described previously (Feng et al., 2013). For assessment of cell proliferation, mice were pulsed with 5-bromo-2-deoxyuridine (BrdU; Sigma-Aldrich) for 1 hr before the mice were euthanized. Sections of paraffin-embedded human or mouse tissues were subjected to immunohistochemical (IHC) analysis as described (Feng et al., 2011). Primary antibodies used for IHC analysis with sections of paraffin-embedded mouse and human tissues are listed in Supplementary file 1. For BrdU staining, tissue sections were treated with 2N HCl at 37°C for 30 min after performing antigen retrieval with citrate buffer (pH 6.0, BioGenex, Fremont, CA). All IHC analyses on human serrated CRC tissues and the mouse tissues were evaluated by three board-certified surgical pathologists with expertise in gastrointestinal cancer diagnosis (N.S., K.S., W.Y.). All of the IHC staining was classified according to the percentage of stained cells. With the exception of CDX2 staining in human CRC specimens, expression of all markers in the human and mouse tissue samples were considered to be negative if <10% of neoplastic cells were observed to be stained, and positive when >10% of neoplastic cells were stained.
We selected five markers for investigation of MSI status in the human serrated CRCs: BAT-25, BAT-26, NR-21, NR-22, NR-24. One primer in each pair was labeled with one of the fluorescent markers FAM, HEX or NED. The five mononucleotide repeat tracts were co-amplified in one multiplex PCR containing 1 mol/L of each primer, 200 mol/L dNTP, 1.5 mmol MgCl2 and 0.75 U Taq DNA polymerase. The pentaplex PCR was performed under the following conditions: denaturation at 94°C for 5 min, 35 cycles of denaturation at 94°C for 30 s, annealing at 55°C for 30 s, and extension at 72°C for 30 s. This was followed by an extension step at 72°C for 7 min (Suraweera et al., 2002). The PCR products were analyzed by ABI 3730XL Genetic Analyzers (Applied Biosystems, Foster City, CA) and Gene Marker-HD software (Softgenetics, State College, PA) was used to calculate the size of each fluorescent PCR product. For the CpG island methylation analysis, sodium bisulfite treatment of genomic DNA and subsequent real-time PCR (MethyLight) were validated and done as previously described (Weisenberger et al., 2005). We quantified DNA methylation at five CIMP-specific promoters: CACNA1G, IGF2, NEUROG1, RUNX3 and SOCS1. CIMP-high was defined as the presence of more than 3 of 5 methylated promoters, CIMP-low as the presence of 0 to 2 of 5 methylated promoters, according to the previously established criteria (Weisenberger et al., 2006).
Microsatellite analysis of mouse tumors was done as described using five microsatellite repeat markers previously shown to be informative in tumors from DNA mismatch repair–deficient mice (Woerner et al., 2015; Kabbarah et al., 2003; Bacher et al., 2005). Tumors were scored as MSI if 2 of 5 markers showed instability. Sodium bisulfite treatment on genomic DNA and subsequent PCR were validated and done as previously described (Song et al., 2014). Amplified DNA fragments were cloned using the TA Cloning Kit into the pCRII plasmid (Invitrogen, Carlsbad, CA). At least 10 clones were then randomly selected and sequenced for each sample.
We tamoxifen treated 8–12 week old mice as the following: (1) Cdx2fl/fl mice; (2) CDX2P-CreERT2 Apcfl/fi mice; (3) CDX2P-CreERT2 Cdx2fl/fl mice; (4) CDX2P-CreERT2 BrafCA mice; (5) CDX2P-CreERT2 Cdx2fl/fl BrafCA mice. Three mice per group were used. Total RNA was extracted and purified from tumors or normal tissues at the colon-cecum junction. We used Affymetrix Mouse Gene 2.1 ST arrays (Affymetrix, Santa Clara, CA), which hold 41345 probe-sets, but we largely analyzed just those 25216 probe-sets that were mapped to Entrez gene IDs. Raw data was processed with the Robust Multi-array Average algorithm (RMA). Data is log2-transformed transcript abundance estimates. We fit a one-way ANOVA model to the five groups of samples. We supply a supplementary excel workbook that holds the same data as the series matrix file, but also holds the probe-set annotation at the time we analyzed the data, and some simple statistical calculations, which selects subsets of the probe-sets as differentially expressed between pairs of groups, as well as significant Cdx2-/- by BRAFV600E interactions. It also gives the homologous human gene IDs we used for enrichment testing, which were 1-to-1 best homologs according to build 68 of NCBI's Homologene. The mouse gene expression data reported here are available from GEO (accession number GSE84650), and include the statistical analysis.
cDNA was synthesized using a high capacity cDNA reverse transcription kit (Applied Biosystems). qRT-PCR was performed with an ABI Prism 7300 Sequence Analyzer using a SYBR green fluorescence protocol (Applied Biosystems). Primer sequences will be provided upon request.
One-way ANOVA model on log-transformed expression data was used to determine p values in qRT-PCR. Kaplan-Meier survival curves were compared by log-rank test. Fisher’s exact test (for 2 × 2 table) and Mantel-Haenszel Chi-Square test of association (for 3 × 2 table) were used to determine significance in human CRC cases. All tests are two-sided except for one-sided Fisher Exact Tests used in Table 2. P-values are not corrected for multiple testing except in Table 2, where false discovery rates are explicitly computed. Sample sizes were chosen based on experience with previous similar experiments, except in the case of the human colon tumor samples where availability was the main constraint.
Use of mononucleotide repeat markers for detection of microsatellite instability in mouse tumorsMolecular Carcinogenesis 44:285–292.https://doi.org/10.1002/mc.20146
Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patientsWorld Journal of Gastroenterology 21:1457–1467.https://doi.org/10.3748/wjg.v21.i5.1457
Maternal Cdx2 is dispensable for mouse developmentDevelopment 139:3969–3972.https://doi.org/10.1242/dev.086025
CDX2 as a prognostic biomarker in stage II and stage III colon cancerNew England Journal of Medicine 374:211–222.https://doi.org/10.1056/NEJMoa1506597
Molecular genetics of colorectal cancerAnnual Review of Pathology: Mechanisms of Disease 6:479–507.https://doi.org/10.1146/annurev-pathol-011110-130235
Gastrointestinal polyposes: clinical, pathological and molecular featuresGastroenterology Clinics of North America 36:927–946.https://doi.org/10.1016/j.gtc.2007.08.009
A panel of repeat markers for detection of microsatellite instability in murine tumorsMolecular Carcinogenesis 38:155–159.https://doi.org/10.1002/mc.10157
Serrated and non-serrated precursor lesions of colorectal cancerDigestive Diseases 33:28–37.https://doi.org/10.1159/000366032
Morphologic reappraisal of serrated colorectal polypsThe American Journal of Surgical Pathology 27:65–81.https://doi.org/10.1097/00000478-200301000-00008
Morphology and microsatellite instability in sporadic serrated and non-serrated colorectal cancerThe Journal of Pathology 207:285–294.https://doi.org/10.1002/path.1850
Analysis of repetitive element DNA methylation by MethyLightNucleic Acids Research 33:6823–6836.https://doi.org/10.1093/nar/gki987
Detection of coding microsatellite frameshift mutations in DNA mismatch repair-deficient mouse intestinal tumorsMolecular Carcinogenesis 54:1376–1386.https://doi.org/10.1002/mc.22213
Chi Van DangReviewing Editor; University of Pennsylvania, United States
In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.
Thank you for submitting your article "BRAFV600E cooperates with CDX2 inactivation to promote serrated colorectal tumorigenesis" for consideration by eLife. Your article has been reviewed by three peer reviewers, one of whom, Chi Van Dang, is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Sean Morrison as the Senior Editor.
The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a response for a possible revised submission.
The manuscript by Sakamoto et al. describes the genomic alterations of serrated colorectal carcinoma (CRC), which has a distinct serrated pathological appearance and occurs in ~10% of CRCs. The authors studied 36 serrated CRCs and found CDX2 loss and/or BRAF mutations in 60% of serrated CRCs. Having identified CDX2 loss and BRAF mutation as hallmarks of serrated CRC, the authors modeled these losses in the mouse and were able to demonstrate cause-and-effect of these alterations and recapitulate a number of features of human serrated adenomas and adenocarcinomas in the mice (Cdx2-/-, Brafmut). The development of the model is predicated on the observation that mutational activation of Braf and loss of Cdx2 expression are common events in human serrated tumors. This particular aspect of the work does not account for a number of published studies that have described the link between Braf, Cdx2 and serrated lesions; for instance Dawson et al., 2014 (PMID: 24166180, not referenced by the authors). Similarly, comprehensive mouse modelling work from Rad et al., showed that Braf is a driver of serrated polyposis (Rad et al., 2013). The current study provides evidence that Cdx2 loss directly contributes to the progression of CRC through the serrated pathway. The model will likely be a useful tool for those studying progression of serrated colonic tumors. Unfortunately, the manuscript is descriptive and does not offer any explanation for why Cdx2 might play such a role in serrated tumor progression. Too often the authors offer correlation as a surrogate of causation, and do not provide direct evidence linking genotype to phenotype.
1) The authors are vague about the details of the animal experiments. Because the paper is driven by the development of this new model, this is important. There is no mention of tumor burden (how many tumors per mouse?), how many showed serrated features, what percentage were invasive (e.g. "Some tumor lesions in each TAM-treated… mouse showed evidence that the serrated glands had invaded the submucosa."). The paper would also be a much stronger demonstration of the new model if more than only 5 mice of the relevant genotype were produced and analysed.
2) The authors use colon organoids, a surrogate ex vivo system, but for the most part, this analysis just re-confirms gene expression changes that were already documented in the (more relevant) in vivo context. The authors are not convincing that they can recapitulate the 'serrated phenotype' in ex vivo organoid culture. In many instances, one can see the same type of cell morphology ("invaginations of epithelial cells into the organoid lumen") in normal cultures. Even if this is a true manifestation of the serrated tumor phenotype, it is a very subjective measure to rely on as the sole method of quantitation for inhibitor treatment studies (Figure 8). There is also little discussion of what this means. Is it another assay to show Braf's role in serrated tumorigenesis, or are the authors suggesting a potential specific application for Braf inhibitors in patients with serrated tumors?
3) The authors use HT29 cells to confirm CDX2/BRAF biology in human CRC, however HT29 cells carry an APC mutation, which the authors imply is a rare event in serrated tumorigenesis. More importantly, the magnitude in gene expression changes does not correlate with the animal model. For instance, ANXA10 is suppressed ~50%, in contrast to the 100-fold change seen in mice. Further, the other 3 genes analyzed show moderate (50%) changes with CDX2 overexpression alone, with only a mild increase in suppression following BRAFi treatment. Also, it is questionable that "the additive effects of CDX2 ectopic expression and BRAF or MAPK inhibition" are shown by western blot in Figure 5B. There is no apparent additional suppression of PDX1 with MEK or BRAF inhibition. Finally, why were these genes chosen? Do other genes on the list show the same trend?
4) The manuscript would be greatly enriched if the authors could use informatics and their gene signature(s) to analyze the available TCGA data and compare them to the findings that loss of CDX2 expression and BRAF mutation is found in serrated CRCs that account for ~20% of cases. In essence, a retrospective bioinformatics study of as many as possible CRC TCGA data to identify the serrated subset of CRCs purely based on informatics would be highly instructive.https://doi.org/10.7554/eLife.20331.032
- Eric R Fearon
- Martin McMahon
- Eric R Fearon
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Human subjects: The colorectal cancers were studied in accordance with the Ethical Guidelines for Human Genome/Gene Research enacted by the Japanese Government. We also studied human benign serrated colorectal lesions obtained from the University of Michigan tissue procurement service through an Institutional Review Board-approved protocol (#00058054).
Animal experimentation: Procedures involving mice for the research described herein have been approved by the University of Michigan's Institutional Animal Care and Use Committee (PRO00005075) and were carried out according to Michigan state and US federal regulations.
- Chi Van Dang, Reviewing Editor, University of Pennsylvania, United States
© 2017, Sakamoto et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.